Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DQ2D
|
|||
| Drug Name |
RG7625
|
|||
| Synonyms |
Petesicatib; UNII-A26QO95U37; A26QO95U37; RG-7625; RO-5459072; Petesicatib [INN]; SCHEMBL700776; GTPL9855; KXAAIORSMACJSI-AEFFLSMTSA-N; RO5459072; 2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-, (2S,4R)-; 1252637-35-6; (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide; (2s,4r)-4-[4-(1-me
Click to Show/Hide
|
|||
| Indication | Autoimmune disease [ICD-11: 4A40-4A45; ICD-9: 279] | Phase 2 | [1] | |
| Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0] | Phase 2 | [1] | ||
| Coeliac disease [ICD-11: DA95; ICD-10: K90.0; ICD-9: 579] | Phase 1 | [1] | ||
| Company |
RocheBasel, Switzerland
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H23F6N5O4S
|
|||
| Canonical SMILES |
CN1C=C(C=N1)C2=CC(=C(C=C2)S(=O)(=O)C3CC(N(C3)C(=O)C4(CC4)C(F)(F)F)C(=O)NC5(CC5)C#N)C(F)(F)F
|
|||
| InChI |
1S/C25H23F6N5O4S/c1-35-11-15(10-33-35)14-2-3-19(17(8-14)24(26,27)28)41(39,40)16-9-18(20(37)34-22(13-32)4-5-22)36(12-16)21(38)23(6-7-23)25(29,30)31/h2-3,8,10-11,16,18H,4-7,9,12H2,1H3,(H,34,37)/t16-,18+/m1/s1
|
|||
| InChIKey |
KXAAIORSMACJSI-AEFFLSMTSA-N
|
|||
| CAS Number |
CAS 1252637-35-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin S (CTSS) | Target Info | Antagonist | [1] |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Tuberculosis | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | |||
| Trafficking and processing of endosomal TLR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.